Top

International Journal of Clinical Oncology

Published in:

01-12-2011 | Original Article

The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control

Authors: Miki Ishibashi, Mitsunobu Kishino, Sunao Sato, Eiichi Morii, Yuzo Ogawa, Katsuyuki Aozasa, Mikihiko Kogo, Satoru Toyosawa

Published in: International Journal of Clinical Oncology | Issue 6/2011

Abstract

Background

Previous reports concerning the prevalence of human papillomavirus (HPV) in oral squamous cell carcinoma (OSCC) have observed varied results. The aim of this study was to evaluate the prevalence of HPV in oral premalignant lesions (OPL) and OSCC. For accurate HPV detection in oral lesions, comparative analysis was performed on cervical lesions as positive controls.

Methods

Fifty-seven cases with OPL and 50 with OSCC were selected. Twenty-nine control cases were selected from cervical lesions. The HPV infection rate was analysed by consensus polymerase chain reaction (PCR) using the My09/My11 and Gp5+/Gp6+ primers, and genotyping detection was employed using a PCR-based micro-array. Immunohistochemical staining for p16^INK4a was performed.

Results

Twenty-eight (96.6%) cases of cervical lesions were positive for HPV by consensus PCR and 24 cases (82.8%) were positive by genotyping. The total HPV-positive rate in cervical lesions was 96.6%. HPV-DNA was detected in nine cases (15.8%) of OPL and six cases (12.0%) of OSCC by consensus PCR. Six cases (10.5%) of OPL and three cases (6.0%) of OSCC were positive by genotyping. The total HPV-positive rate in oral lesions was 22.4% (26.3% of OPL and 18.0% of OSCC). In cervical lesions, immunohistochemistry of p16^INK4a identified 27 cases (93.1%) as positive. Fifteen cases (26.3%) of OPL and eight cases (16.0%) of OSCC were positive for p16^INK4a.

Conclusions

The HPV infection and p16^INK4a-positive rates in oral lesions are lower than previously reported. This suggests that HPV may not play a major role in oral lesions although its involvement cannot completely be ruled out.

Smeets SJ, Braakhuis BJ, Abbas S et al (2006) Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 25:558–2564CrossRef

Herrero R, Castellsagué X, Pawlita M et al (2003) Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 95:1772–1783PubMed

Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720PubMedCrossRef

Zhao M, Rosenbaum E, Carvalho AL et al (2005) Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer 117:605–610PubMedCrossRef

Hafkamp HC, Speel EJ, Haesevoets A et al (2003) A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8. Int J Cancer 107:394–400PubMedCrossRef

O’Regan EM, Toner ME, Finn SP et al (2008) p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. Hum Pathol 39:452–458PubMedCrossRef

Chuang AY, Chuang TC, Chang S et al (2008) Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol 44:915–919PubMedCrossRef

Scully C (2002) Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral Oncol 38:227–234PubMedCrossRef

Schwartz SM, Daling JR, Doody DR et al (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626–1636PubMedCrossRef

10.

Ostör AG (1993) Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12:186–192PubMedCrossRef

11.

Bosch FX, Lorincz A, Muñoz N et al (2002) The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55:244–265PubMedCrossRef

12.

Schiffman MH, Bauer HM, Hoover RN et al (1993) Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 85:958–964PubMedCrossRef

13.

Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRef

14.

Muñoz N, Bosch FX, de Sanjosé S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527PubMedCrossRef

15.

Longworth MS, Laimins LA (2004) Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68:362–372PubMedCrossRef

16.

Scheffner M, Werness BA, Huibregtse JM et al (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136PubMedCrossRef

17.

Werness BA, Levine AJ, Howley PM (1990) Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79PubMedCrossRef

18.

Dyson N, Howley PM, Münger K et al (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243:934–937PubMedCrossRef

19.

Sano T, Oyama T, Kashiwabara K et al (1998) Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 153:1741–1748PubMedCrossRef

20.

Syrjänen K, Syrjänen S, Lamberg M et al (1983) Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg 12:418–424PubMedCrossRef

21.

Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475PubMedCrossRef

22.

Goon P, Stanley MA, Ebmeyer J et al (2009) HPV & head and neck cancer: a descriptive update. Head Neck Oncol 1:36PubMedCrossRef

23.

Gale N, Pilch BZ, Sidransky D et al (2005) Epithelial precursor lesions. In: Barnes L, Eveson JW, Reichart P, Sidransky D (eds) World Health Organization classification of tumours: pathology and genetics of head and neck tumours. IARC Press, Lyon, pp 177–179

24.

Saiki RK, Scharf S, Faloona F et al (1985) Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350–1354PubMedCrossRef

25.

Karlsen F, Kalantari M, Jenkins A et al (1996) Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 34:2095–2100PubMed

26.

Kong CS, Balzer BL, Troxell ML et al (2007) p16^INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol 31:33–43PubMedCrossRef

27.

Balaram P, Nalinakumari KR, Abraham E et al (1995) Human papillomaviruses in 91 oral cancers from Indian betel quid chewers—high prevalence and multiplicity of infections. Int J Cancer 61:450–454PubMedCrossRef

28.

Koskinen WJ, Chen RW, Leivo I et al (2003) Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107:401–406PubMedCrossRef

29.

Andl T, Kahn T, Pfuhl A et al (1998) Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Res 58:5–13PubMed

30.

Bouda M, Gorgoulis VG et al (2000) “High risk” HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol 13(6):644–653PubMedCrossRef

31.

D’Costa J, Saranath D et al (1998) Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. Oral Oncol 34(5):413–420PubMedCrossRef

32.

Kulmala SM, Shabalova IP, Petrovitchev N et al (2007) Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 79:771–781PubMedCrossRef

33.

Clifford GM, Rana RK, Franceschi S et al (2005) Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14:1157–1164PubMedCrossRef

34.

Klaes R, Friedrich T, Spitkovsky D et al (2001) Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 92:276–284PubMedCrossRef

35.

Lambert AP, Anschau F, Schmitt VM (2006) p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 80:192–196PubMedCrossRef

36.

Ishikawa M, Fujii T, Saito M et al (2006) Overexpression of p16 INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 16:347–353PubMedCrossRef

37.

Lakshmi S, Rema P, Somanathan T (2009) p16^INK4A is a surrogate marker for high-risk and malignant cervical lesions in the presence of human papillomavirus. Pathobiology 76:141–148PubMedCrossRef

38.

Gologan O, Barnes EL, Hunt JL (2005) Potential diagnostic use of p16INK4A, a new marker that correlates with dysplasia in oral squamoproliferative lesions. Am J Surg Pathol 29:792–796PubMedCrossRef

39.

Cunningham LL Jr, Pagano GM, Li M et al (2006) Overexpression of p16INK4 is a reliable marker of human papillomavirus-induced oral high-grade squamous dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:77–81PubMedCrossRef

40.

Ferreux E, Lont AP, Horenblas S et al (2003) Evidence for at least three alternative mechanisms targeting the p16INK4A/cyclin D/Rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J Pathol 201:109–118PubMedCrossRef

41.

Nemes JA, Deli L, Nemes Z et al (2006) Expression of p16(INK4A), p53, and Rb proteins are independent from the presence of human papillomavirus genes in oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:344–352PubMedCrossRef

42.

Smeets SJ, Hesselink AT, Speel EJ et al (2007) A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 121:2465–2472PubMedCrossRef

43.

Patrick KH, Joseph AC (2004) The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med 15:188–196CrossRef

Title: The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control
Authors: Miki Ishibashi
Mitsunobu Kishino
Sunao Sato
Eiichi Morii
Yuzo Ogawa
Katsuyuki Aozasa
Mikihiko Kogo
Satoru Toyosawa
Publication date: 01-12-2011
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0236-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2011

Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors

Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review

A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer

A case of primary alveolar soft part sarcoma of the uterine cervix and a review of the literature

Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer